Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Noble Paul W., Albera Carlo, Bradford Williamson Z., Costabel Ulrich, du Bois Roland M., Fagan Elizabeth A., Fishman Robert S., Glaspole Ian, Glassberg Marilyn K., Lancaster Lisa, Lederer David J., Leff Jonathan A., Nathan Steven D., Pereira Carlos A., Swigris Jeffrey J., Valeyre Dominique, King Talmadge E.
Source: Eur Respir J 2016; 47: 243-253
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Noble Paul W., Albera Carlo, Bradford Williamson Z., Costabel Ulrich, du Bois Roland M., Fagan Elizabeth A., Fishman Robert S., Glaspole Ian, Glassberg Marilyn K., Lancaster Lisa, Lederer David J., Leff Jonathan A., Nathan Steven D., Pereira Carlos A., Swigris Jeffrey J., Valeyre Dominique, King Talmadge E.. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: